BioLineRx - ADR Financials

$2.71

$0.02 (0.74%)

As on 04-Sep-2026 12:24EDT

Market cap

$11 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	1.40	1.19	28.94	4.80	--	--
Cost of Revenue	0.35	0.76	9.26	3.69	0.65	0.70
Gross Profit	1.05	0.43	19.68	1.11	-0.65	-0.70
Operating Expenses	11.97	10.80	40.09	50.80	29.16	24.78
Operating Profit (EBIT)	-10.92	-10.37	-20.41	-49.69	-29.16	-24.78
Other Income	--	--	--	--	--	--
Profit before Tax	-9.75	-2.04	-9.22	-60.61	-24.95	-27.05
Provision for Tax	--	--	--	0.00	-4.21	1.09
Profit after Tax (Net Income)	-8.89	-1.18	-9.22	-60.61	-24.95	-27.05
Minority Interest	0.99	0.85	--	--	--	--
Consolidated Profit	--	--	--	--	--	-27.05

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	16.67	18.20	13.46	13.22	50.84	68.09
Minority Interest	0.99	--	--	--	--	--
Non-Current Liabilities	4.34	5.44	10.04	19.85	14.86	3.59
Current Liabilities	13.62	12.12	15.41	42.78	10.68	9.72
Total Liabilities	52.42	40.90	38.91	63.93	76.38	81.39

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	17.22	17.22	11.80	16.74	24.38	23.99
Current Assets	21.58	23.68	27.10	47.18	52.00	57.40
Total Assets	52.42	40.90	38.91	63.93	76.38	81.39
Total Debt*	9.07	10.15	15.04	11.59	12.32	4.65
Net Current Assets	7.96	11.56	11.70	16.33	41.32	47.69

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-8.14	-43.87	-22.61	-26.24	-23.57
Cash Flow from Investing Activities	--	-8.61	29.37	1.44	4.01	-38.22
Cash from Financing Activities	--	8.95	20.66	15.06	20.44	57.75
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-2.15	-0.27	-4.62	-33.72	-19.34	-24.49
Cash EPS ($)	--	-0.15	-2.58	-32.95	-18.84	-23.85
Adjusted Book Value ($)	--	4.18	6.74	7.36	39.41	61.62
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.87	-21.98	-12.58	-20.34	-21.33
Free Cash Flow per Share ($)	--	-1.88	-22.00	-12.74	-20.59	-21.42

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-4.17	-34.59	-137.79	-36.72	-52.81
ROE (%)	-43.66	-7.48	-69.11	-189.23	-41.96	-60.04
ROA (%)	-16.17	-2.97	-17.93	-86.40	-31.63	-42.05
EBIT Margin (%)	-615.96	-63.22	-0.51	-1,218.13	--	--
Net Margin (%)	-633.66	-99.58	-31.86	-1,262.79	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-93.72	-0.96	5.03	--	--	--
EBIT Growth (%)	-267.28	-411.51	99.75	-156.53	12.57	8.62
Net Profit Growth (%)	-132.63	87.16	84.79	-142.93	7.77	9.88
EPS Growth (%)	-26.17	0.94	0.86	-0.74	0.21	0.66
Book Value Growth (%)	-64.01	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-10.18	-0.05	-0.05	-0.03	-0.08
Price / Book Value	0.72	0.66	0.03	0.21	0.01	0.03
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.11	-5.91	-1.05	0.50	1.72	1.98
Close Price ($)	2.30	2.77	8.56	62.80	23.60	81.60
High Price ($)	7.77	14.70	63.60	101.20	87.60	253.60
Low Price ($)	2.25	2.30	7.48	22.00	21.80	78.00
Market Cap ($ Cr)	11.36	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	0.20	0.56	1.12	0.88	0.24	0.07
Short term debt to equity ratio	0.28	0.26	0.37	0.28	0.04	0.04
Current Ratio	1.58	1.95	1.76	1.10	4.87	5.91
Quick Ratio	1.43	1.78	1.56	1.06	4.85	5.89
Interest Coverage	-7.77	-0.58	-0.02	-26.96	-10.56	-26.49

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	134.76	38.34	13.35	14.75	--	--
Asset Turnover	0.03	0.03	0.56	0.07	--	--
Receivable days	--	663.18	28.85	54.37	--	--
Inventory Days	--	1,273.60	100.51	106.35	90.42	72.44
Payable days	--	2,183.86	324.36	882.21	3,499.75	2,987.82
Cash Conversion Cycle	--	-247.09	-195.01	-721.49	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.